Nurse Mpho Matloane prepares a syringe stuffed with the drug Lenacapavir which he prepares to manage to Kegoratile Aphane (left) on the Phedisong clinic in Ga-Rankuwa, north-west of Pretoria, on Dec. 2, 2025.
Ihsaan Haffe/AFP through Getty Photos
disguise caption
toggle caption
Ihsaan Haffe/AFP through Getty Photos
JOHANNESBURG — South Africa rolled out a brand new, biannual HIV prevention drug on Friday that has the potential to drastically lower an infection charges, however U.S. support cuts imply entry can be restricted.
Lenacapavir, a sort of Pre-exposure Prophylaxis (PrEP), is injected into the abdomen each six months and is principally failproof at stopping high-risk people from contracting the virus.
South Africa isn’t the primary African nation to introduce injectable Lenacapavir. The drug is rolling out throughout Africa quicker than any HIV prevention choice to date, and South Africa turns into the ninth nation on the continent to launch it. However in a nation with the very best variety of HIV circumstances on the earth, the long-acting injection is being hailed as a possible sport changer.
“The launch at present of Lenacapavir marks a turning level in our nation’s combat towards HIV. To us, this unbelievable, unbelievable therapy is not only a drugs or a drug, to us it represents a serious turning level in South Africa’s nationwide story,” mentioned South African President Cyril Ramaphosa on the launch.
The rollout is starting in 360 well being amenities in high-burden districts.
South Africa, which has about 8 million folks dwelling with HIV, in response to UNAIDS, has made nice strides in therapy, with a majority of the inhabitants on Antiretroviral medication. However prevention remains to be a problem, with about 160,000 new infections yearly.
Most of these infections happen in adolescent ladies and younger ladies aged 15 to 24, with about 1,000 on this demographic contaminated every week. Among the many causes for this are unequal relationships, typically transactional, that these women and girls have with older males.
South Africa already has some PrEP within the type of a every day capsule, however adherence is an issue. Consultants are hopeful that Lenacapavir might be the breakthrough that makes prevention more practical and accessible.
“Lenacapavir offers us one thing we have now by no means had earlier than in HIV prevention: a twice-yearly choice that may be considerably simpler to suit into folks’s lives,” Dr. Saiqa Mullick, a PrEP specialist at Wits RHI on the College of Witwatersrand, informed NPR.
However to essentially flip the tide on the epidemic, Mullick says South Africa will want excess of what Worldwide well being financing partnership the World Fund has supplied — sufficient to place about 456,000 folks on the drug over two years.
“We now have a game-changing know-how, however influence will rely upon implementation. A breakthrough product solely modifications the epidemic if it reaches the individuals who want it most,” she mentioned.
At the moment, entry is being hampered by two issues: the very fact the Trump administration slashed the U.S. President’s Emergency Plan for AIDS Reduction (PEPFAR) funding to South Africa final 12 months, and the shortage of an inexpensive generic.
“U.S. funding cuts have affected HIV prevention infrastructure, group programmes, outreach, youth companies and key inhabitants companies. The cuts have undermined prevention programmes simply as South Africa wants them for Lenacapavir rollout,” mentioned Mullick. “Some alternative financing is rising however it would not totally exchange the dimensions of PEPFAR funding.”
Linda-Gail Bekker, an HIV knowledgeable who leads the Desmond Tutu Well being Basis, additionally famous the influence of the U.S. cuts.
“Had Pepfar been in place, we might have I feel been the recipients of extra Len doses, because it occurs, we’re getting at the least some from the World Fund, however clearly we might have been in a position to obtain each World Fund in addition to Pepfar assist on this regard,” she mentioned.
At the moment the price of Lenacapavir, made by U.S. pharmaceutical firm Gilead, is prohibitive: about $28,000 per particular person a 12 months within the U.S.
However generics are on the best way after a deal to make them accessible to 120 low and middle-income nations, says Mullick. And sub-Saharan African nations are a precedence.
“South Africa can be searching for native manufacturing capability to enhance regional entry and scale back dependency on exterior provide,” she mentioned.
The generic model of Lenacapavir is predicted to change into accessible in 2027 at a price of round $40 per particular person per 12 months.
“Clearly as soon as the generics come on-line we’re very hopeful that the South African authorities can even be capable to make a big contribution in the direction of buying Len on a bigger scale,” mentioned Bekker.
Scientific modeling exhibits that if one to 2 million HIV-negative folks take the shot between now and 2043, AIDS might stop to be a serious public well being drawback in South Africa.
